MD Anderson is applying comprehensive team science to improve
treatment and clinical outcomes for triple-negative breast cancer
(TNBC). The Breast Cancer Moon Shot™ is leading several new and
exciting projects that can quickly make a difference in the detection
and treatment of TNBC.
While the tumor cells in some triple-negative breast cancer patients
respond well to standard therapies, there are other patients whose
tumors do not respond well. Finding out why some tumors have lower
response to chemotherapy, how treatment resistance can be overcome,
and developing new, more effective therapies for these TNBC patients
are important goals of the Breast Cancer Moon Shot.
Because we’ve treated a large number of patients diagnosed with this
uncommon cancer, our clinicians and investigators can search for
answers in unprecedented amounts of data. This will not only help
defeat TNBC, but also provide the basis for therapies to treat other
types of breast cancers. Knowledge gained by studying this disease
will likely benefit patients with other cancers as well.
STORIES OF HOPE
When Erika Archer Lewis found out that she carried the BRCA1 genetic mutation and thus faced a greater risk of breast and ovarian cancers, she opted for a mastectomy.